The chronic obstructive pulmonary disease comorbidity spectrum in japan differs from that in western countries

Respiratory Investigation

Volumn 53, Issue 6, 2015, Pages 259-270

  Takahashi, Saeko ^a   Betsuyaku, Tomoko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Comorbidity; COPD; Japanese; Regional characteristics

Indexed keywords

AGING; ASTHMA; BODY MASS; CANCER STAGING; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EMPHYSEMA; ETHNIC DIFFERENCE; FORCED EXPIRATORY VOLUME; HUMAN; JAPAN; LUNG CANCER; LUNG FIBROSIS; MALNUTRITION; METABOLIC SYNDROME X; MUSCLE ATROPHY; OSTEOPOROSIS; OXYGEN THERAPY; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; REVIEW; SEX RATIO; SMOKING; SOCIAL STATUS; TREATMENT DURATION; WESTERN HEMISPHERE; CANADA; CARDIOVASCULAR DISEASES; COMPLICATION; LUNG NEOPLASMS; MUSCULOSKELETAL DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY FIBROSIS; SOUTH KOREA; TURKEY; UNITED STATES;

CANADA; CARDIOVASCULAR DISEASES; COMORBIDITY; DEPRESSION; EMPHYSEMA; HUMANS; JAPAN; LUNG NEOPLASMS; MALNUTRITION; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASES; OSTEOPOROSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY FIBROSIS; REPUBLIC OF KOREA; TURKEY; UNITED STATES;

EID: 84954197861     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2015.05.005     Document Type: Review

References (116)

1. Berry C.E., Wise R.A. Mortality in COPD: causes, risk factors, and prevention. COPD 2010, 7:375-382.
2. Corsonello A., Antonelli Incalzi R., Pistelli R., et al. Comorbidities of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2011, 17:S21-S28.
3. Vanfleteren L.E., Spruit M.A., Groenen M., et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:728-735.
4. Tatsumi K., Kasahara Y., Kurosu K., et al. Clinical phenotypes of COPD: results of a Japanese epidemiological survey. Respirology 2004, 9:331-336.
5. Tanabe N., Muro S., Hirai T., et al. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011, 183:1653-1659.
6. Fukuchi Y., Fernandez L., Kuo H.P., et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology 2011, 16:825-835.
7. Suzuki M., Makita H., Ito Y.M., et al. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J. 2014, 43:1289-1297.
8. McGarvey L.P., John M., Anderson J.A., et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax 2007, 62:411-415.
9. Haruna A., Muro S., Nakano Y., et al. CT scan findings of emphysema predict mortality in COPD. Chest 2010, 138:635-640.
10. Miyazaki M., Nakamura H., Chubachi S., et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res 2014, 15:13.
11. Nishimura M., Makita H., Nagai K., et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:44-52.
12. Müllerova H., Maselli D.J., Locantore N., et al. Hospitalized exacerbations of chronic obstructive pulmonary disease: risk factors and outcomes in the ECLIPSE cohort. Chest 2014.
13. Miller J., Edwards L.D., Agustí A., et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013, 107:1376-1384.
14. Anthonisen N.R., Skeans M.A., Wise R.A., et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005, 142:233-239.
15. Jenkins C.R., Jones P.W., Calverley P.M., et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59.
16. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; updated 2014. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdf.
17. Divo M., Cote C., de Torres J.P., et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161.
18. Committee for the 4th edition of the COPD guidelines of the Japanese Respiratory Society. Guidelines for the diagnosis and treatment of Chronic Obstructive Pulmonary Disease: 4th edition.
19. Donaldson G.C., Hurst J.R., Smith C.J., et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137:1091-1097.
20. Mannino D.M., Doherty D.E., Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006, 100:115-122.
21. Sin D.D., Man S.F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005, 2:8-11.
22. Shibata Y., Inoue S., Igarashi A., et al. A lower level of forced expiratory volume in 1s is a risk factor for all-cause and cardiovascular mortality in a Japanese population: the Takahata study. PLoS One 2013, 8:e83725.
23. Peinado V.I., Barbera J.A., Ramirez J., et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998, 274:L908-L913.
24. Vaidyula V.R., Criner G.J., Grabianowski C., et al. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res 2009, 124:259-261.
25. Kaczmarek P., Sladek K., Stepien E., et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009, 102:1176-1182.
26. Yoon H.I., Li Y., Man S.F., et al. The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. Chest 2012, 142:893-899.
27. Tomoda K., Yoshikawa M., Itoh T., et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest 2007, 132:135-140.
28. Watanabe R., Tanaka T., Aita K., et al. Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab 2015, 33:392-400.
29. Ferguson G.T., Calverley P.M., Anderson J.A., et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. Chest 2009, 136:1456-1465.
30. Lehouck A., Boonen S., Decramer M., et al. COPD, bone metabolism, and osteoporosis. Chest 2011, 139:648-657.
31. Graat-Verboom L., van den Borne B.E., Smeenk F.W., et al. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 2011, 26:561-568.
32. McEvoy C.E., Ensrud K.E., Bender E., et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:704-709.
33. Nuti R., Siviero P., Maggi S., et al. Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO study. Osteoporos Int 2009, 20:989-998.
34. Papaioannou A., Parkinson W., Ferko N., et al. Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int. 2003, 14:913-917.
35. Jørgensen N.R., Schwarz P., Holme I., et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 2007, 101:177-185.
36. Chubachi S., Nakamura H., Sasaki M., et al. Polymorphism of LRP5 gene and emphysema severity are associated with osteoporosis in Japanese patients with or at risk for COPD. Respirology 2015, 20:286-295.
37. Ohara T., Hirai T., Muro S., et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008, 134:1244-1249.
38. Graat-Verboom L., Smeenk F.W., van den Borne B.E., et al. Progression of osteoporosis in patients with COPD: a 3-year follow up study. Respir Med 2012, 106:861-870.
39. Kiyokawa H., Muro S., Oguma T., et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. COPD 2012, 9:235-242.
40. Ogura-Tomomatsu H., Asano K., Tomomatsu K., et al. Predictors of osteoporosis and vertebral fractures in patients presenting with moderate-to-severe chronic obstructive lung disease. COPD 2012, 9:332-337.
41. Majumdar S.R., Villa-Roel C., Lyons K.J., et al. Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respir Med. 2010, 104:260-266.
42. Kjensli A., Mowinckel P., Ryg M.S., et al. Low bone mineral density is related to severity of chronic obstructive pulmonary disease. Bone 2007, 40:493-497.
43. Sin D.D., Man J.P., Man S.F. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003, 114:10-14.
44. Breyer M.K., Spruit M.A., Hanson C.K., et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One 2014, 9:e98013.
45. Mishima M., Oku Y., Muro S., et al. Relationship between dyspnea in daily life and psycho-physiologic state in patients with chronic obstructive pulmonary disease during long-term domiciliary oxygen therapy. Intern Med 1996, 35:453-458.
46. Horita N., Kaneko T., Shinkai M., et al. Depression in Japanese patients with chronic obstructive pulmonary disease: a cross-sectional study. Respir Care 2013, 58:1196-1203.
47. Iguchi A., Senjyu H., Hayashi Y., et al. Relationship between depression in patients with COPD and the percent of predicted FEV(1), BODE index, and health-related quality of life. Respir Care 2013, 58:334-339.
48. Hanania N.A., Müllerova H., Locantore N.W., et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011, 183:604-611.
49. Omachi T.A., Katz P.P., Yelin E.H., et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med 2009, 122. 778e9-15.
50. Light R.W., Merrill E.J., Despars J.A., et al. Prevalence of depression and anxiety in patients with COPD. Relationship to functional capacity. Chest 1985, 87:35-38.
51. van Manen J.G., Bindels P.J., Dekker F.W., et al. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002, 57:412-416.
52. Wagena E.J., Arrindell W.A., Wouters E.F., et al. Are patients with COPD psychologically distressed?. Eur Respir J 2005, 26:242-248.
53. Chavannes N.H., Huibers M.J., Schermer T.R., et al. Associations of depressive symptoms with gender, body mass index and dyspnea in primary care COPD patients. Fam Pract 2005, 22:604-607.
54. Al-shair K., Dockry R., Mallia-Milanes B., et al. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir Med 2009, 103:1572-1579.
55. Quint J.K., Baghai-Ravary R., Donaldson G.C., et al. Relationship between depression and exacerbations in COPD. Eur Respir J 2008, 32:53-60.
56. Yohannes A.M., Roomi J., Waters K., et al. Quality of life in elderly patients with COPD: measurement and predictive factors. Respir Med 1998, 92:1231-1236.
57. Young C.B., Fang D.Z., Zisook S. Depression in Asian-American and Caucasian undergraduate students. J Affect Disord 2010, 125:379-382.
58. Jamil H., Grzybowski M., Hakim-Larson J., et al. Factors associated with self-reported depression in Arab, Chaldean and African Americans. Ethn Dis 2008, 18:464-470.
59. Kunik M.E., Roundy K., Veazey C., et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005, 127:1205-1211.
60. Di Marco F., Verga M., Reggente M., et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med 2006, 100:1767-1774.
61. Gudmundsson G., Gislason T., Janson C., et al. Depression, anxiety and health status after hospitalisation for COPD: a multicentre study in the Nordic countries. Respir Med 2006, 100:87-93.
62. Cully J.A., Graham D.P., Stanley M.A., et al. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 2006, 47:312-319.
63. Lacasse Y., Rousseau L., Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. Thorax 2002, 57:412-416.
64. Xu W., Collet J.P., Shapiro S., et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 2008, 178:913-920.
65. Ng T.P., Niti M., Tan W.C., et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007, 167:60-67.
66. Mannino D.M., Thorn D., Swensen A., et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
67. Rana J.S., Mittleman M.A., Sheikh J., et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004, 27:2478-2484.
68. Cazzola M., Bettoncelli G., Sessa E., et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010, 80:112-119.
69. The investigation of Ministry of Health, Labour and Welfare; 2012, . http://www.mhlw.go.jp/bunya/kenkou/eiyou/h24-houkoku.html.
70. Takeuchi H., Saitoh S., Takagi S., et al. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the national cholesterol education program-adult treatment panel III to Japanese men - the Tanno and Sobetsu study. Hypertens Res 2005, 28:203-208.
71. Park S.K., Larson J.L. Metabolic syndrome and associated factors in people with chronic obstructive pulmonary disease. West J Nurs Res 2014, 36:620-642.
72. Marquis K., Maltais F., Duguay V., et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005, 25:226-232.
73. Akpinar E.E., Akpinar S., Ertek S., et al. Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk Toraks 2012, 60:230-237.
74. Park B.H., Park M.S., Chang J., et al. Chronic obstructive pulmonary disease and metabolic syndrome: a nationwide survey in Korea. Int J Tuberc Lung Dis 2012, 16:694-700.
75. Kokubo H. Modern physician 2006, 26:675-684. (Japanese).
76. Hersh C.P., Make B.J., Lynch D.A., et al. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med 2014, 14:164.
77. Garcia-Aymerich J., Gómez F.P., Benet M., et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011, 66:430-437.
78. Minas M., Kostikas K., Papaioannou A.I., et al. The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without co-morbidities. COPD 2011, 8:414-420.
79. Díez-Manglano J., Barquero-Romero J., Almagro P., et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med 2014, 9:419-425.
80. Küpeli E., Ulubay G., Ulasli S.S., et al. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010, 38:76-82.
81. Breyer M.K., Spruit M.A., Hanson C.K., et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One 2014, 9:e98013.
82. Jee S.H., Sull J.W., Park J., et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006, 355:779-787.
83. Vestbo J., Prescott E., Almdal T., et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006, 173:79-83.
84. Mannino D.M., Thorn D., Swensen A., et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
85. Yeh H.C., Punjabi N.M., Wang N.Y., et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2008, 31:741-746.
86. Walter R.E., Beiser A., Givelber R.J., et al. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003, 167:911-916.
87. Donahoe M., Rogers R.M. Nutritional assessment and support in chronic obstructive pulmonary disease. Clin Chest Med 1990, 11:487-504.
88. Obase Y., Mouri K., Shimizu H., et al. Nutritional deficits in elderly smokers with respiratory symptoms that do not fulfill the criteria for COPD. Int J Chron Obstruct Pulmon Dis 2011, 6:679-683.
89. Agusti A., Soriano J.B. COPD as a systemic disease. COPD 2008, 5:133-138.
90. Kiri V.A., Soriano J., Visick G., et al. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J 2010, 19:57-61.
91. Brenner D.R., McLaughlin J.R., Hung R.J. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One 2011, 6:e17479.
92. Aberle D.R., Adams A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011, 365:395-409. National Lung Screening Trial Research Team.
93. Hashimoto N., Matsuzaki A., Okada Y., et al. Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients. BMC Pulm Med 2014, 14:14.
94. Tockman M.S., Anthonisen N.R., Wright E.C., et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987, 106:512-518.
95. de Torres J.P., Marín J.M., Casanova C., et al. Lung cancer in patients with chronic obstructive pulmonary disease - incidence and predicting factors. Am J Respir Crit Care Med 2011, 184:913-919.
96. Mannino D.M., Aguayo S.M., Petty T.L., et al. Low lung function and incident lung cancer in the United States: data from the first national health and nutrition examination survey follow-up. Arch Intern Med 2003, 163:1475-1480.
97. Hiwatari N., Shimura S., Takishima T. Pulmonary emphysema followed by pulmonary fibrosis of undetermined cause. Respiration 1993, 60:354-358.
98. Washko G.R., Hunninghake G.M., Fernandez I.E., et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011, 364:897-906.
99. Usui K., Tanai C., Tanaka Y., et al. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology 2011, 16:326-331.
100. Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax 2009, 64:728-735.
101. Miravitlles M., Calle M., Soler-Cataluña J.J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol 2012, 48:86-98.
102. Menezes A.M., Montes De Oca M., Pérez-Padilla R., et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014, 145:297-304.
103. Soriano J.B., Davis K.J., Coleman B., et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003, 124:474-481.
104. Fukuchi Y., Nishimura M., Ichinose M., et al. COPD in Japan: the Nippon COPD epidemiology study. Respirology 2004, 9:458-465.
105. Kobayashi S., Yanai M., Hanagama M., et al. The burden of chronic obstructive pulmonary disease in the elderly population. Respir Investig 2014, 52:296-301.
106. Bale G., Martínez-Camblor P., Burge P.S., et al. Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respir Med 2008, 102:1468-1472.
107. Jones P.W., Willits L.R., Burge P.S., et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003, 21:68-73.
108. Vilkman S., Keistinen T., Tuuponen T., et al. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 1997, 64:281-284.
109. Zieliński J. Circumstances of death in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1998, 53:324-330.
110. Keistinen T., Tuuponen T., Kivelä S.L. Survival experience of the population needing hospital treatment for asthma or COPD at age 50-54 years. Respir Med 1998, 92:568-572.
111. Pauwels R.A., Löfdahl C.G., Laitinen L.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999, 340:1948-1953.
112. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
113. Fabricius P., Løkke A., Marott J.L., et al. Prevalence of COPD in Copenhagen. Respir Med 2011, 105:410-417.
114. Tashkin D.P., Celli B., Senn S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
115. Celli B., Decramer M., Kesten S., et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:948-955.
116. Watson L., Vonk J.M., Löfdahl C.G., et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med 2006, 100:746-753.